Clinical trials: Influenza A H3N2
Influenza A
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03999554
- Testing
- LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine
- Where
- 4 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza Vaccine
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate safety and immunogenicity of the investigational Sing2016 M2SR H3N2 influenza vaccine delivered intranasally to a healthy adult population age 50…
- Trial name
- NCT04785794
- Testing
- Sing2016 M2SR H3N2 influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza
The purpose of this study is to determine the safety and efficacy of TCN-032 given to healthy adult volunteers that have been inoculated with the influenza A virus
- Trial name
- NCT01719874
- Testing
- TCN-032
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Theraclone Sciences, Inc.
Influenza Vaccine
Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults
This is a randomized, double-blind, double-dummy, placebo-controlled Phase 1b study evaluating the safety and immunogenicity of the investigational Cam2020 M2SR H3N2 influenza vaccine delivered IN alone or concomitantly with…
- Trial name
- NCT05163847
- Testing
- Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV
- Where
- 6 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Flu
Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers
The purpose is of this study is to assess the safety and tolerability of three dose levels of H3N2 M2SR influenza vaccine versus placebo delivered intranasally to healthy adult subjects.
- Trial name
- NCT02822105
- Testing
- the H3N2 M2SR monovalent influenza vaccine
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza A H3N2
Study Examining PrEP-001 in Healthy Subjects
Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.
- Trial name
- NCT03220048
- Testing
- PrEP-001
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza A H3N2, Influenza A H1N1
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza, or the flu, is an infectious respiratory disease that can range in severity from mild to severe to even death. This study aims to evaluate a treatment for people who are hospitalized with the flu.
- Trial name
- NCT03315104
- Testing
- FLU-IGIV
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- Emergent BioSolutions
Influenza
Banlangen Granules Anti-seasonal Influenza Study
This study aimed to evaluate the efficacy and safety of the nature herbal medicine Banlangen granules in patients infected with seasonal influenza A (H1N1,H3N2) and influenza B virus.
- Trial name
- BLG (NCT02232945)
- Testing
- oseltamivir phosphate, Banlangen (Radix Isatidis) granules
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Influenza, Human
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age.
- Trial name
- NCT06087640
- Testing
- aQIV or aTIV, QIV or TIV
- Where
- 255 sites in United States, Australia and 19 more
- Volunteers
- 38,769 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Influenza A
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
The goal of this clinical study is to prove the no less immunogenicity of the Grippol Quadrivalent vaccine compared to the Grippol plus vaccine in children aged 6 months to 5 years (inclusive) for three identical strains of the…
- Conditions
- Influenza, Influenza A, Influenza, Human, Influenza Type B
- Trial name
- NCT06385821
- Testing
- Grippol Quadrivalent, Grippol Plus
- Where
- 14 sites in Russia
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Influenza A H3N2
Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age In Part A, up to 40 participants will be randomly allocated to one of…
- Trial name
- NCT06613737
- Testing
- Influenza A H3N2 virus dose arm 1, Influenza A H3N2 virus dose arm 2, Influenza A H3N2 virus dose arm 3
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older
The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.
- Trial name
- NCT00848848
- Testing
- Trivalent Influenza Vaccine, Trivalent Influenza Vaccine + high A, Trivalent Influenza Vaccine + ¼ dose adjuvant
- Where
- Belgium
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People
The purpose of this study is to determine the immunogenicity, tolerability and dose-effect relationship of one 0.5 mL intramuscular (IM) injection of four FLUVAL AB-like trivalent influenza vaccines containing either 3.5μgHA…
- Trial name
- NCT01408290
- Testing
- Vaccination with FAB-3511, Vaccination with FAB-6011, Vaccination with FAB-9011
- Where
- 4 sites in Hungary
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
The study will characterise Influenza A/Perth/16/2009(H3N2) virus in healthy participants using the viral challenge model. The study includes two cohorts.
- Trial name
- NCT02525055
- Testing
- Infectious titre 1 (H3N2), Infectious titre 2 (H3N2), Infectious titre 3 (H3N2)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Hvivo